Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.

Nicolo' Gebbia, Antonio Russo, Laura Rocci, Fabrizio Battistoni, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini, Michele Gavasci, Marianna Silletta, Di Cuonzo

Risultato della ricerca: Article

25 Citazioni (Scopus)

Abstract

Introduction: Angiogenesis has been correlated with increased invasion and metastases in a variety of human neoplasms. Inadequate inhibition of the growth of tumor microvessels by anticancer agents may result in treatment failure, rated clinically as progressive or stable disease. We designed this trial to investigate the modification of the vascular endothelial growth factor (VEGF) and interferon-c (IFN-c) in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. Materials and methods: Forty-five metastatic colorectal cancer patients were prospectively evaluated for circulating levels of VEGF and IFN-c during the treatment with cetuximab (initial dose of 400 mg/m2 , followed by weekly infusions of 250 mg/m2 ) plus weekly irinotecan (90 mg/m2 ). The circulating levels of the cytokines were assessed at the following time points: just before and at 1, 21, 50 and 92 days after the start of cetuximab plus irinotecan treatment. Results: Basal serum VEGF median levels were significantly decreased just at the first day (after the first treatment infusion (P = 0.016). The VEGF persisted at the following time points reaching the highest statistical significance 92 days after the first infusion (P < 0.0001). On the contrary, IFN-c values showed a statistical significant increase one day after the first infusion (P < 0.0001). This effect persisted 21 days after the treatment start (P = 0.001), but was no more evident at the following time points. Moreover, a linear regression model with variance analysis showed a significant negative correlation between VEGF and IFN-c values 1, 21 and 50 days after the treatment beginning (P = 0.002, 0.001 and 0.047, respectively). Conclusions: This study suggests that a cetuximab may induce a modulation of VEGF circulating levels. The reduction of VEGF serum levels is a sudden and long lasting phenomenon. Moreover, in our study we identified a IFN-c increase, even if the specific role of this behavior remains to be investigated.
Lingua originaleEnglish
pagine (da-a)835-841
Numero di pagine7
RivistaAnnals of Oncology
Volume17
Stato di pubblicazionePublished - 2006

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cita questo

Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. / Gebbia, Nicolo'; Russo, Antonio; Rocci, Laura; Battistoni, Fabrizio; Vincenzi, Bruno; Tonini, Giuseppe; Santini, Daniele; Gavasci, Michele; Silletta, Marianna; Di Cuonzo.

In: Annals of Oncology, Vol. 17, 2006, pag. 835-841.

Risultato della ricerca: Article

Gebbia, N, Russo, A, Rocci, L, Battistoni, F, Vincenzi, B, Tonini, G, Santini, D, Gavasci, M, Silletta, M & Di Cuonzo 2006, 'Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.', Annals of Oncology, vol. 17, pagg. 835-841.
Gebbia, Nicolo' ; Russo, Antonio ; Rocci, Laura ; Battistoni, Fabrizio ; Vincenzi, Bruno ; Tonini, Giuseppe ; Santini, Daniele ; Gavasci, Michele ; Silletta, Marianna ; Di Cuonzo. / Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. In: Annals of Oncology. 2006 ; Vol. 17. pagg. 835-841.
@article{5d73af60902244bdad7d48b9f53a9e61,
title = "Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.",
abstract = "Introduction: Angiogenesis has been correlated with increased invasion and metastases in a variety of human neoplasms. Inadequate inhibition of the growth of tumor microvessels by anticancer agents may result in treatment failure, rated clinically as progressive or stable disease. We designed this trial to investigate the modification of the vascular endothelial growth factor (VEGF) and interferon-c (IFN-c) in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. Materials and methods: Forty-five metastatic colorectal cancer patients were prospectively evaluated for circulating levels of VEGF and IFN-c during the treatment with cetuximab (initial dose of 400 mg/m2 , followed by weekly infusions of 250 mg/m2 ) plus weekly irinotecan (90 mg/m2 ). The circulating levels of the cytokines were assessed at the following time points: just before and at 1, 21, 50 and 92 days after the start of cetuximab plus irinotecan treatment. Results: Basal serum VEGF median levels were significantly decreased just at the first day (after the first treatment infusion (P = 0.016). The VEGF persisted at the following time points reaching the highest statistical significance 92 days after the first infusion (P < 0.0001). On the contrary, IFN-c values showed a statistical significant increase one day after the first infusion (P < 0.0001). This effect persisted 21 days after the treatment start (P = 0.001), but was no more evident at the following time points. Moreover, a linear regression model with variance analysis showed a significant negative correlation between VEGF and IFN-c values 1, 21 and 50 days after the treatment beginning (P = 0.002, 0.001 and 0.047, respectively). Conclusions: This study suggests that a cetuximab may induce a modulation of VEGF circulating levels. The reduction of VEGF serum levels is a sudden and long lasting phenomenon. Moreover, in our study we identified a IFN-c increase, even if the specific role of this behavior remains to be investigated.",
author = "Nicolo' Gebbia and Antonio Russo and Laura Rocci and Fabrizio Battistoni and Bruno Vincenzi and Giuseppe Tonini and Daniele Santini and Michele Gavasci and Marianna Silletta and {Di Cuonzo}",
year = "2006",
language = "English",
volume = "17",
pages = "835--841",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients.

AU - Gebbia, Nicolo'

AU - Russo, Antonio

AU - Rocci, Laura

AU - Battistoni, Fabrizio

AU - Vincenzi, Bruno

AU - Tonini, Giuseppe

AU - Santini, Daniele

AU - Gavasci, Michele

AU - Silletta, Marianna

AU - Di Cuonzo, null

PY - 2006

Y1 - 2006

N2 - Introduction: Angiogenesis has been correlated with increased invasion and metastases in a variety of human neoplasms. Inadequate inhibition of the growth of tumor microvessels by anticancer agents may result in treatment failure, rated clinically as progressive or stable disease. We designed this trial to investigate the modification of the vascular endothelial growth factor (VEGF) and interferon-c (IFN-c) in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. Materials and methods: Forty-five metastatic colorectal cancer patients were prospectively evaluated for circulating levels of VEGF and IFN-c during the treatment with cetuximab (initial dose of 400 mg/m2 , followed by weekly infusions of 250 mg/m2 ) plus weekly irinotecan (90 mg/m2 ). The circulating levels of the cytokines were assessed at the following time points: just before and at 1, 21, 50 and 92 days after the start of cetuximab plus irinotecan treatment. Results: Basal serum VEGF median levels were significantly decreased just at the first day (after the first treatment infusion (P = 0.016). The VEGF persisted at the following time points reaching the highest statistical significance 92 days after the first infusion (P < 0.0001). On the contrary, IFN-c values showed a statistical significant increase one day after the first infusion (P < 0.0001). This effect persisted 21 days after the treatment start (P = 0.001), but was no more evident at the following time points. Moreover, a linear regression model with variance analysis showed a significant negative correlation between VEGF and IFN-c values 1, 21 and 50 days after the treatment beginning (P = 0.002, 0.001 and 0.047, respectively). Conclusions: This study suggests that a cetuximab may induce a modulation of VEGF circulating levels. The reduction of VEGF serum levels is a sudden and long lasting phenomenon. Moreover, in our study we identified a IFN-c increase, even if the specific role of this behavior remains to be investigated.

AB - Introduction: Angiogenesis has been correlated with increased invasion and metastases in a variety of human neoplasms. Inadequate inhibition of the growth of tumor microvessels by anticancer agents may result in treatment failure, rated clinically as progressive or stable disease. We designed this trial to investigate the modification of the vascular endothelial growth factor (VEGF) and interferon-c (IFN-c) in advanced colorectal cancer patients during treatment with a weekly combination of cetuximab plus irinotecan. Materials and methods: Forty-five metastatic colorectal cancer patients were prospectively evaluated for circulating levels of VEGF and IFN-c during the treatment with cetuximab (initial dose of 400 mg/m2 , followed by weekly infusions of 250 mg/m2 ) plus weekly irinotecan (90 mg/m2 ). The circulating levels of the cytokines were assessed at the following time points: just before and at 1, 21, 50 and 92 days after the start of cetuximab plus irinotecan treatment. Results: Basal serum VEGF median levels were significantly decreased just at the first day (after the first treatment infusion (P = 0.016). The VEGF persisted at the following time points reaching the highest statistical significance 92 days after the first infusion (P < 0.0001). On the contrary, IFN-c values showed a statistical significant increase one day after the first infusion (P < 0.0001). This effect persisted 21 days after the treatment start (P = 0.001), but was no more evident at the following time points. Moreover, a linear regression model with variance analysis showed a significant negative correlation between VEGF and IFN-c values 1, 21 and 50 days after the treatment beginning (P = 0.002, 0.001 and 0.047, respectively). Conclusions: This study suggests that a cetuximab may induce a modulation of VEGF circulating levels. The reduction of VEGF serum levels is a sudden and long lasting phenomenon. Moreover, in our study we identified a IFN-c increase, even if the specific role of this behavior remains to be investigated.

UR - http://hdl.handle.net/10447/26534

M3 - Article

VL - 17

SP - 835

EP - 841

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -